VCNX
vs
S&P 500
VCNX
S&P 500
Over the past 12 months, VCNX has underperformed S&P 500, delivering a return of -86% compared to the S&P 500's +12% growth.
Stocks Performance
VCNX vs S&P 500
Performance Gap
VCNX vs S&P 500
Performance By Year
VCNX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vaccinex Inc
Glance View
Vaccinex, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Rochester, New York and currently employs 39 full-time employees. The company went IPO on 2018-08-09. The firm is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate, pepinemab (VX15/2503), is a humanized monoclonal antibody that binds and blocks the signaling activity of semaphorin 4D (SEMA4D). The company is focused on the development of pepinemab for the treatment of certain cancer indications, in particular, head and neck squamous cell carcinoma (HNSCC) as well as neurodegenerative diseases, including Huntington's disease (HD), and Alzheimer's disease, (AD). The firm has discovered VX5 using its ActivMAb antibody discovery platform. VX5 is a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, and is in preclinical development for the treatment of multiple sclerosis (MS) and for other autoimmune disorders.
